Chi Shang Tai

Direttore/Membro del Consiglio presso ZICOM GROUP LIMITED

46 anni

Health Technology

Producer Manufacturing

Consumer Services

Profilo

Chi Shang Tai is the founder of Histoindex Pte Ltd.
He currently holds a position as a Non-Independent Non-Executive Director at Zicom Group Ltd.
Dr. Tai has an undergraduate and doctorate degree from Auckland University.

Posizioni attive di Chi Shang Tai

Società	Posizione	Inizio
ZICOM GROUP LIMITED	Direttore/Membro del Consiglio	30/11/2020
Histoindex Pte Ltd. Histoindex Pte Ltd. Medical SpecialtiesHealth Technology Histoindex Pte Ltd. is a medtech/healthcare company based in Singapore, Singapore. The stain-free AI platform is currently involved in multiple FDA clinical trials for nonalcoholic steatohepatitis (NASH) and has benefitted more than 150 research and academic institutes, CROs, and biopharma companies worldwide in drug discovery and development efforts for fibrotic diseases and cancers. Founded in 2010, the Singaporean company specializes in its proprietary integrated stain-free AI digital pathology platform that accurately quantifies histological features and fine measurements critical for the evaluation of therapeutic efficacy in clinical trials. The company was founded by Gideon Ho, Chi-Shang Tai, and Gideon Ho has been the CEO since incorporation.	Fondatore	01/04/2010

Tutte le posizioni attive di Chi Shang Tai

Formazione di Chi Shang Tai

Auckland University

Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Chi Shang Tai

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
ZICOM GROUP LIMITED	Producer Manufacturing

Aziende private	1
Histoindex Pte Ltd. Histoindex Pte Ltd. Medical SpecialtiesHealth Technology Histoindex Pte Ltd. is a medtech/healthcare company based in Singapore, Singapore. The stain-free AI platform is currently involved in multiple FDA clinical trials for nonalcoholic steatohepatitis (NASH) and has benefitted more than 150 research and academic institutes, CROs, and biopharma companies worldwide in drug discovery and development efforts for fibrotic diseases and cancers. Founded in 2010, the Singaporean company specializes in its proprietary integrated stain-free AI digital pathology platform that accurately quantifies histological features and fine measurements critical for the evaluation of therapeutic efficacy in clinical trials. The company was founded by Gideon Ho, Chi-Shang Tai, and Gideon Ho has been the CEO since incorporation.	Health Technology